Resources
About Us
Home Report
Store
Next Generation Sequencing Services Market
Next Generation Sequencing Services Market by Type (Targeted, RNA, De Novo, WES, WGS), Technology (Sequencing by Synthesis, Ion Semiconductor, SMRT, Nanopore), Application (Research, Clinical [Oncology, Reproductive]), End User – Global Forecast to 2031
Report ID:MRHC - 104341 Pages: 284 Jun-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 HoursNext Generation Sequencing Services Market Size & Forecast
The Next Generation Sequencing Services Market is expected to register a CAGR of 19.8% from 2024 to 2031 to reach $24.44 billion by 2031. The growth of this market is mainly driven by the declining costs of sequencing procedures, the development & approval of new targeted therapies, the rising prevalence of cancer, partnerships between NGS service providers & pharmaceutical companies, the high cost of implementing sequencing infrastructure, and technological advancements in NGS. Furthermore, the increasing applications of NGS in cancer & agri-genomics research and advancements in sequencing data analytics are expected to generate market growth opportunities. However, regulatory & standardization concerns in diagnostic testing, the installation of in-house NGS facilities in large hospitals & research institutes, and the ethical issues & costs related to non-invasive prenatal genetic testing are major challenges for the stakeholders in this market.
Next Generation Sequencing Services Market Growth Drivers
Decreasing Costs of Sequencing
Recent advancements in genomics research have substantially reduced the costs of genome sequencing procedures. In the past few years, the availability of advanced NGS technologies has lowered sequencing costs and significantly reduced the time required for DNA sequencing. According to the National Human Genome Research Institute (NHGRI), the cost of sequencing a human genome decreased from USD 29,092 in 2010 to USD 562 in 2021.
As the cost of sequencing is declining, the adoption of NGS services has increased rapidly. NGS has enabled the discovery of genetically targeted drugs and blood tests that can detect cancer at early stages. It has also enabled diagnosis for people with rare diseases. The declining cost of sequencing has increased its adoption in clinical applications. Thus, the declining sequencing costs are expected to drive the growth of the NGS services market.
Rising Prevalence of Cancer
Cancer poses a huge burden globally, leading to a decrease in the quality of life and even mortality. There is a high prevalence of cancer, accounting for 159.8 million cancer cases in 2022. Advancements in next-generation sequencing (NGS) technology are changing the way doctors diagnose and treat cancer. New targeted cancer treatments that use genomic data to provide patient-specific treatments are known as precision oncology. It is a rapidly developing field that has already entered mainstream clinical practices. Precision oncology involves the molecular profiling of cancer cells to identify targetable alterations, also known as biomarkers. NGS services are increasingly being used for genomic profiling in targeted cancer therapy applications due to the decreasing costs and turnaround times of NGS, improvements in bioinformatics analyses, and the harmonization of knowledge bases to facilitate the clinical interpretation of genomic results.
Click here to: Get a Free Sample Copy of this report
Next Generation Sequencing Services Market Trends
Installation of In-house NGS Systems to Hinder Market Growth
The advantages of NGS and the plummeting costs of NGS procedures have led to the installation of in-house NGS systems. Various large hospital chains and academic & research institutes are increasingly setting up in-house NGS facilities for their sequencing needs. These in-house facilities help healthcare professionals by reducing turnaround times for test results, enabling them to effectively plan personalized treatments for their patients. These in-house facilities help researchers improve research efficiency by reducing turnaround times and retaining sample quality. They also help organizations improve their revenue channels, adversely affecting the revenues of core NGS service providers.
Thus, the increasing installation of in-house sequencing platforms and facilities among large-scale hospitals and academic & research institutes may hamper the revenues of NGS service providers, affecting the growth of the NGS services market.
Growing Utilization of NGS Services in Disease Diagnostics and Precision Medicine
NGS is widely used for cancer testing and is available in many diagnostic laboratories. Apart from cancer, NGS technologies are also increasingly utilized for diagnosing various other diseases. NGS can be used to diagnose a wide range of diseases, from novel microbial agents that cause epidemics to heterogeneous mutations that cause complex inherited disorders. NGS is the best method for diagnosing complex diseases involving multiple genes. Autism, connective tissue disorders, cardiomyopathies, and disorders of sex development are a few such diseases.
The utilization of NGS for the molecular detection and genotyping of infectious disease pathogens has been growing. It is also being used for public health surveillance. Isolated pathogens can be identified using NGS directly from the samples. However, the implementation of NGS in medical practice has been slow due to its high costs and the availability of cheaper alternative methods. However, the advantages of NGS in terms of time and accuracy have led to the widespread utilization of NGS in disease diagnosis. Also, in some cases, NGS is the only available method of diagnosis. NGS services are being rapidly adopted, especially for noninvasive prenatal testing to detect fetal aneuploidies in high-risk pregnancies.
Next Generation Sequencing Services Market Opportunity
Growing Applications of NGS in Agri-Genomics
The increasing global population has put extreme pressure on land and animal resources to meet the growing food needs. Improvements in agricultural technologies, irrigation, inputs, and pricing policies have further outgrown the pressure to increase production. Due to this increasing demand, sequencing procedures have been used in animal and plant breeding to derive products with desired traits.
There is an increasing need to breed novel crops that produce higher yields, are heat and drought-tolerant, and require lesser pesticide use due to the rapidly growing world population and the increasing environmental pressure caused by climate change. Genomic advancements have made it possible to accelerate the development of crops with favorable agronomic traits. Agriculture genomics refers to the use of genetics in agriculture to increase crop and livestock productivity and sustainability. The traditional plant-breeding practices for producing new crop varieties were time-consuming and could result in biodiversity loss. Therefore, the popularity of high-throughput next-generation sequencing (NGS) technologies is growing as they can help identify causal genetic factors by sequencing a species' whole genome and transcriptome.
Next Generation Sequencing Services Market Analysis: Key Findings
By Type: In 2024, the Targeted Sequencing Services Segment is Expected to Account for the Largest Share of the NGS Services Market
Based on type, the NGS services market is segmented into targeted sequencing services, whole genome sequencing services, RNA sequencing services, exome sequencing services, de novo sequencing services, ChIP sequencing services, methyl sequencing services, and other NGS services. In 2024, the targeted sequencing services segment is expected to account for the largest share of 43.9% of the NGS services market. The large share of this segment is attributed to the increased use of targeted sequencing in precision medicine, its higher cost efficiency compared to other sequencing services, the increased number of clinical applications for diagnosing diseases and monitoring patient health, its rapid turnaround time, and its growing importance in cancer research and drug discovery.
However, the whole genome sequencing services segment is slated to register the highest CAGR of 20.3% during the forecast period of 2024-2031. The wide applications of whole genome sequencing, growing genomic research, declining costs of sequencing, and favorable initiatives by governments and private institutions for genomic research to explore its clinical applications drive the segment growth.
Whole genome sequencing has several applications, including in the analysis of tumors, causes and progression of diseases, selection of plants and animals for agricultural breeding programs, and analysis of common genetic variations among populations. It also enables the identification of known virulence factors and deriving a comprehensive resistance profile of pathogens toward antibiotic drugs. Whole genome sequencing has been used to identify genes linked to cancer, diabetes, immune disorders, and other diseases. Numerous novel genetic aberrations and related potential therapeutic targets have been discovered in several cancers using whole genome (or whole-exome) sequencing.
By Technology: In 2024, the Sequencing by Synthesis Segment is Expected to Account for The Largest Share of The Market
Based on technology, the NGS services market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing (IOS), single-molecule real-time sequencing (SMRT), nanopore sequencing, and DNA nanoball sequencing. In 2024, the sequencing by synthesis (SBS) segment is expected to account for the largest share of 62.9% of the NGS services market. The large share of this segment is attributed to its benefits, including higher yield of error-free throughput, base call values exceeding Q30, and superior accuracy in DNA sequencing compared to other sequencing technologies.
SBS provides the most accurate data across a broad range of applications, with the highest yield of error-free reads and a base call value above Q30, which helps researchers reach strong biological conclusions. This is one of the key factors contributing to the large share of SBS among all sequencing technologies. Further, due to the ability of SBS to generate several gigabases of DNA sequence per run, large mammalian genomes can be sequenced in a week using this technology. SBS is gradually eliminating the need for gel-based size-fractionation by providing much higher throughput than other sequencing technologies.
The nanopore sequencing segment is expected to register the highest CAGR of 20.9% during the forecast period. The benefits offered by nanopore sequencing technology, such as inexpensive sample preparation, label-free ultra-long reads, high throughput, and lower material requirements compared to other sequencing technologies, drive the growth of this segment.
The technique is used in cancer diagnosis and treatment by detecting and accurately quantifying MicroRNA, a cancer biomarker. Hence, it is used in cancer diagnosis, staging, progression, prognosis, and treatment response. In addition, this technology produces fast results and is also used to detect infectious diseases. For instance, MinION (by Oxford Nanopore Technologies) was used to detect and confirm Ebola samples in Africa in under 15 minutes.
By Application: the Research Applications Segment is Expected to Account for the Largest Share of the NGS Services Market
Based on application, the NGS services market is segmented into research applications and clinical applications. In 2024, the research applications segment is expected to account for the largest share of the NGS services market. This large segmental share is mainly attributed to the increasing demand for gene-based medicines, growing investments in drug research and development activities, and increasing research programs for personalized medicine, leading to an increase in the approval for molecule-based therapies (molecular entities). For instance, the number of new molecular entities (NMEs) approved by the U.S. FDA increased from 30 in 2011 to 50 in 2021 in the U.S.
However, the clinical applications segment is expected to register the highest CAGR during the forecast period of 2024 to 2031. The growth of this segment is attributed to factors such as the growing adoption of next-generation sequencing for oncology applications, the increasing demand for precision medicine in cancer therapy, and the rising need for specific cancer gene-targeting diagnostic tests.
With an increasing number of cancer patients globally, there is a growing need for efficient & advanced methods for cancer diagnosis and effective targeted treatment. The adoption of NGS technology in medicine is expected to improve diagnostic accuracy and reduce overall treatment costs. The extensive research conducted in oncology is expected to lead to the development and launch of cancer gene-targeting tests, driving the adoption of NGS services for clinical applications during the forecast period.
By End User: In 2024, the Hospitals & Clinics Segment is Estimated to Account for the Largest Share of the NGS Services Market
Based on end user, the NGS services market is segmented into hospitals & clinics, pharmaceutical & biotechnology companies, academic institutes & research centers, and other end users. In 2024, the hospitals & clinics segment is estimated to account for the largest share of the NGS services market. The large share of this segment is attributed to factors such as high capital requirements for building in-house NGS capabilities in hospitals & clinics, the rising prevalence of cancer and other chronic diseases, the growing demand for advanced medical treatments, and the rising number of biomarker-based therapies.
However, the pharmaceutical & biotechnology industry segment is slated to register the highest CAGR during the forecast period of 2024-2031. Growing R&D activities and investments, rising prevalence of chronic diseases, growing adoption of NGS services by the pharma and biopharma companies for identification of biomarkers to develop new therapies, and growing use of the NGS services for in bioprocess development to improve the efficiency and yield of bioproduction drives the segment growth.
NGS also plays an important role in biomarker discovery. Pharmaceutical & biotechnology companies are employing NGS services to identify and validate biomarkers that can be used in developing new diagnostic tests and therapies. Biomarkers are measurable indicators of a biological state or process that can be used to diagnose, monitor, or predict the progression of a disease. NGS-based biomarker discovery typically involves using transcriptomics, genomics, or epigenomics approaches to identify changes in gene expression, genetic variations, or epigenetic modifications associated with a particular disease or condition. NGS enables the simultaneous analysis of thousands or even millions of genes, making it a powerful tool for identifying biomarkers that other methods might not detect.
Geographical Analysis
In 2024, North America is expected to account for the largest share of 45.5% of the NGS services market. The large share of North America in the NGS services market is primarily attributed to the presence of leading NGS service providers in the region, favorable government initiatives for genomics research, growing applications of NGS-based research, declining cost of sequencing coupled with the rising awareness of NGS, increasing research investments by pharmaceutical and biopharmaceutical companies, increasing cancer prevalence, and favorable reimbursement scenario in the region.
However, the Asia-Pacific region is slated to register the highest CAGR of 23.2% during the forecast period of 2024-2031. Growing healthcare and pharmaceutical sectors due to growing investments and supporting initiatives, the growing prevalence of chronic diseases coupled with rising healthcare expenditures are the major factors attributed to this region's growth.
Countries like China, Japan, India, and Singapore aim to become competitive in the global biotech market, paving the way for many research and development activities in this domain. India and China have established themselves well in the global biotech outsourcing industry. Compared to Western countries, a large, skilled, and affordable workforce has given these countries an added advantage to further the growth in the biotech industry. This has attracted a lot of investments from foreign players. Such investments are pushing the demand for NGS services across Asia-Pacific.
Next Generation Sequencing Services Market: Key Companies
The report includes a competitive landscape based on an extensive assessment of the key strategic developments that market participants adopted over the past four years. The key players profiled in the next generation sequencing services market report include Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), Eurofins Scientific S.E. (Luxembourg), Macrogen, Inc. (South Korea), LGC Limited (U.K.), GENEWIZ, Inc. (U.S.), Beijing Genomics Institute (China), MedGenome, Inc. (U.S.), DNA Link, Inc. (South Korea), Novogene Co., Ltd. (China), CD Genomics (U.S.), SeqLL, Inc. (U.S.), Otogenetics Corporation (U.S.), Foundation Medicine, Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), and Invitae Corporation (U.S.).
Next Generation Sequencing Services Industry Overview: Latest Developments from Key Industry Players
- In October 2023, QIAGEN N.V. (Netherlands) partnered with Myriad Genetics Laboratories, Inc. (U.S) to deliver services and products to pharmaceutical companies. This enabled the development and commercialization of proprietary cancer tests for the U.S. clinical market and provided distributable companion diagnostic test kits for the global market.
- In November 2023, Quest Diagnostics (U.S.) collaborated with Scipher Medicine Corporation (U.S.), a precision immunology company, to expand patients' access to diagnostic services and advance precision medicine for rheumatoid arthritis (RA).
- In February 2023, Eurofins Genomics LLC (Luxembourg) launched a whole-plasmid sequencing service using Oxford Nanopore technology. This service uses next-generation sequencing (NGS) generation 3 technology to provide quicker turnaround times.
Next Generation Sequencing Services Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
284 |
|
Format |
|
|
Forecast Period |
2024–2031 |
|
Base Year |
2023 |
|
CAGR (Value) |
19.8% |
|
Market Size (Value) |
USD 24.44 Billion by 2031 |
|
Segments Covered |
By Type
By Technology
By Application
By End User
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Ireland, Netherlands, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, New Zealand, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa |
|
Key Companies |
Animal Genetics, Inc. (U.S), Zoetis Inc. (U.S), Mars Petcare (Part of Mars, Incorporated) (U.S.), Embark Veterinary, Inc. (U.S.), Neogen Corporation (U.S.), Basepaws Inc., LABOKLIN GMBH & CO.KG (Germany), Generatio GmbH (Germany), Vetgen LLC (U.S.), FarmLab Diagnostics (Ireland) and EasyDNA (Part of Genetic Technologies Limited) (U.S.). |
Key questions answered in the next generation sequencing services market report:
The next generation sequencing services market covers the market size & forecasts the various NGS services used by hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies, academics & research institutes, and other end users for clinical and research applications. The next generation sequencing services market studied in this report involves the value analysis of various segments and sub-segments of NGS services at regional and country levels.
The next generation sequencing services market is projected to reach $24.44 billion by 2031, at a CAGR of 19.8% during the forecast period.
Based on type, the target sequencing services segment is estimated to account for the largest share of the next generation sequencing services market in 2024. This segment's large share is mainly attributed to its relatively lower cost, faster turnaround time, and accurate and easy-to-interpret results for studies of disease-related genes.
The sequencing by synthesis segment is estimated to register the fastest CAGR during the forecast period. Factors such as the high adoption of Illumina's NGS platforms, its broad range of research and clinical applications, high reliability, and high demand for high-throughput sequencing at lower costs are driving the growth of this technology in the NGS services market.
The decreasing cost of NGS sequencing procedures, development, and approval of new targeted therapies, rising prevalence of cancer, partnerships between NGS service providers & pharma companies, high cost of sequencing infrastructure, and technological advancements in NGS services have been considered to have a positive impact on the next generation sequencing services market. In addition, the increasing application of NGS in cancer and agri-genomics research and advancements in sequencing data analytics provide significant opportunities for the next generation sequencing service providers.
Key companies operating in the next generation sequencing services market are Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), Eurofins Scientific S.E. (Luxembourg), Macrogen, Inc. (South Korea), LGC Limited (U.K.), GENEWIZ, Inc. (U.S.), Beijing Genomics Institute (China), MedGenome, Inc. (U.S.), DNA Link, Inc. (South Korea), Novogene Co., Ltd. (China), CD Genomics (U.S.), SeqLL, Inc. (U.S.), Otogenetics Corporation (U.S.), Foundation Medicine, Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), and Invitae Corporation (U.S.).
Emerging economies like China and India are projected to offer significant growth opportunities for players in this market. Improvement in the healthcare infrastructure, rising research & development activities, and the growing number of patients suffering from gene-associated disorders are the factors that will offer significant growth opportunities in this region.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Declining Costs of Sequencing Procedures
4.2.2. Development and Approval of New Targeted Therapies
4.2.3. High Costs of Implementing Sequencing Infrastructure
4.2.4. Development and Approval of New Targeted Therapies
4.2.5. Rising Cancer Prevalence
4.2.6. Technological Advancements in NGS
4.3. Restraints
4.3.1. Availability of Alternative Technologies
4.3.2. Lack of Skilled Professionals for Sample Preparation & Analysis
4.3.3. Low Chances of Positive Actionable Mutations for Precision Medicine
4.4. Opportunities
4.4.1. Increasing Application of NGS in Cancer & Agri-genomics
4.4.2. Advancements in Sequencing Data Analysis
4.5. Challenges
4.5.1. Regulatory & Standardization Concerns in Diagnostic Testing
4.5.2. Installation of In-house NGS Facilities in Large Hospitals & Research Institutes
4.5.3. Ethical Issues and Costs Related to Noninvasive Prenatal Genetic Testing
4.6. Porter’s Five Forces Analysis
4.6.1. Bargaining Power of Buyers
4.6.2. Bargaining Power of Suppliers
4.6.3. Threat of Substitutes
4.6.4. Threat of New Entrants
4.6.5. Degree of Competition
4.7. Pricing Analysis
4.8. Regulatory Analysis
4.8.1. Overview
4.8.2. North America
4.8.2.1. U.S.
4.8.2.2. Canada
4.8.3. Europe
4.8.4. Asia-Pacific
4.8.4.1. China
4.8.4.2. Japan
4.8.4.3. India
4.8.5. Latin America
4.8.6. Middle East
4.9. Industry & Technology Trends
4.9.1. Installation of In-house NGS Systems to Hinder Market Growth
4.9.2. Growing Utilization of NGS Services in Disease Diagnostics and Precision Medicine
5. NGS Services Market Assessment—by Type
5.1. Overview
5.2. Targeted Sequencing Services
5.3. RNA Sequencing Services
5.4. Whole Genome Sequencing Services
5.5. De Novo Sequencing Services
5.6. Exome Sequencing Services
5.7. ChIP Sequencing Services
5.8. Methyl Sequencing Services
5.9. Other NGS Services
6. NGS Services Market Assessment—by Technology
6.1. Overview
6.2. Sequencing by Synthesis
6.3. Ion Semiconductor Sequencing
6.4. Single-molecule Real-time Sequencing (SMRT)
6.5. Nanopore Sequencing
6.6. DNA Nanoball Sequencing
7. NGS Services Market Assessment—by Application
7.1. Overview
7.2. Research Applications
7.2.1. Drug Discovery
7.2.2. Agriculture & Animal Research
7.2.3. Other Research Applications
7.3. Clinical Applications
7.3.1. Oncology
7.3.2. Reproductive Health
7.3.3. Infectious Diseases
7.3.4. Other Clinical Applications
8. NGS Services Market Assessment—by End User
8.1. Overview
8.2. Hospitals and Diagnostic Laboratories
8.3. Pharmaceutical & Biotechnology Companies
8.4. Academic Institutes & Research Centers
8.5. Other End Users
9. NGS Services Market Assessment — by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.6. Middle East & Africa
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Market Share Analysis (2022)
10.4.1. Eurofins Scientific S.E.
10.4.2. Illumina, Inc.
10.4.3. Foundation Medicine, Inc. (Subsidiary of F. Hoffmann-La Roche AG) (U.S.)
10.4.4. Invitae Corporation (U.S.)
10.4.5. Beijing Genomics Institute (BGI) (China)
10.4.6. Novogene Co., Ltd. (China)
10.4.7. Perkinelmer, Inc. (U.S.)
10.5. Competitive Dashboard
10.5.1. Industry Leaders
10.5.2. Market Differentiators
10.5.3. Vanguards
10.5.4. Emerging Companies
11. Company Profiles(Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
11.1. Illumina, Inc.
11.2. Eurofins Scientific S.E.
11.3. Invitae Corporation
11.4. Foundation Medicine, Inc. (Subsidiary of F. Hoffmann-La Roche AG)
11.5. Beijing Genomics Institute (BGI)
11.6. Novogene Co., Ltd.
11.7. Perkinelmer, Inc.
11.8. Macrogen, Inc.
11.9. QIAGEN N.V.
11.10. LGC Limited
11.11. GENEWIZ, Inc. (Subsidiary of Azenta, Inc.)
11.12. MedGenome, Inc.
11.13. DNA Link, Inc.
11.14. CD Genomics
11.15. Otogenetics Corporation
11.16. Quest Diagnostics Incorporated
(Note: SWOT analyses of the top 5 companies will be provided.)
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Incidence of Common Genetic Disorders
Table 2 Number of New Cancer Cases, by Type, 2020 Vs. 2030
Table 3 Biomarkers and Corresponding Targeted Therapies Currently Available
Table 4 Pricing of Key NGS Service Providers
Table 5 Regulatory Authorities Governing In vitro Diagnostics & NGS Products, by Country/Region
Table 6 NGS Services: Standards and Compliance Guidelines for Laboratories
Table 7 Biomarkers and Corresponding Targeted Therapies Currently Available
Table 8 Global NGS Services Market, by Type, 2022–2031 (USD Million)
Table 9 Global Targeted Sequencing Services Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Global RNA Sequencing Services, by Country/Region, 2022–2031 (USD Million)
Table 11 Global Whole Genome Sequencing Services Market, by Country/Region, 2022–2031 (USD Million)
Table 12 Global De Novo Sequencing Services Market, by Country/Region, 2022–2031 (USD Million)
Table 13 Global Exome Sequencing Services Market, by Country/Region, 2022–2031 (USD Million)
Table 14 Global ChIP Sequencing Services Market, by Country/Region, 2022–2031 (USD Million)
Table 15 Global Methyl Sequencing Services Market, by Country/Region, 2022–2031 (USD Million)
Table 16 Global Other NGS Services Market, by Country/Region, 2022–2031 (USD Million)
Table 17 Global NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 18 Global NGS Services Market for Sequencing by Synthesis, by Country/Region, 2022–2031 (USD Million)
Table 19 Global NGS Services Market for Ion Semiconductor Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 20 Global NGS Services Market for Single-molecule Real-time Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 21 Global NGS Services Market for Nanopore Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 22 Global DNA Nanoball Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 23 Global NGS Services Market, by Application, 2022–2031 (USD Million)
Table 24 Global NGS Services Market for Research Applications, by Type 2022–2031 (USD Million)
Table 25 Global NGS Services Market for Research Applications, by Country/Region, 2022–2031 (USD Million)
Table 26 Global NGS Services Market for Drug Discovery, by Country/Region, 2022–2031 (USD Million)
Table 27 Global NGS Services Market for Agriculture & Animal Research, by Country/Region, 2022–2031 (USD Million)
Table 28 Global NGS Services Market for Other Research Applications, by Country/Region, 2022–2031 (USD Million)
Table 29 Global NGS Services Market for Clinical Applications, by Type 2022–2031 (USD Million)
Table 30 Global NGS Services Market for Clinical Applications, by Country/Region, 2022–2031 (USD Million)
Table 31 Currently Available Targeted Therapies and Corresponding Biomarkers
Table 32 Global NGS Services Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 33 Global NGS Services Market for Reproductive Health, by Country/Region, 2022–2031 (USD Million)
Table 34 HIV Prevalence Among Adults, by Region (2017 Vs. 2021)
Table 35 Global NGS Services Market for Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
Table 36 Global NGS Services Market for Other Clinical Applications, by Country/Region, 2022–2031 (USD Million)
Table 37 Global NGS Services Market, by End User, 2022–2031 (USD Million)
Table 38 Global NGS Services Market for Hospitals and Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 39 Global NGS Services Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022–2031 (USD Million)
Table 40 Global NGS Services Market for Academic Institutes & Research Centers, by Country/Region, 2022–2031 (USD Million)
Table 41 Global NGS Services Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 42 Global NGS Services Market, by Country/Region, 2022–2031 (USD Million)
Table 43 North America: NGS Services Market, by Country, 2022–2031 (USD Million)
Table 44 North America: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 45 North America: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 46 North America: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 47 North America: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 48 North America: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 49 North America: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 50 U.S.: Key Macro & Micro Indicators
Table 51 U.S.: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 52 U.S.: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 53 U.S.: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 54 U.S.: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 55 U.S.: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 56 U.S.: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 57 Canada: Key Macro & Micro Indicators
Table 58 Canada: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 59 Canada: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 60 Canada: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 61 Canada: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 62 Canada: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 63 Canada: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 64 Europe: NGS Services Market, by Country/Region, 2022–2031 (USD Million)
Table 65 Europe: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 66 Europe: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 67 Europe: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 68 Europe: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 69 Europe: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 70 Europe: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 71 Germany: Key Macro & Micro Indicators
Table 72 Germany: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 73 Germany: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 74 Germany: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 75 Germany: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 76 Germany: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 77 Germany: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 78 France: Key Macro & Indicators
Table 79 France: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 80 France: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 81 France: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 82 France: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 83 France: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 84 France: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 85 U.K.: Key Macro & Micro Indicators
Table 86 U.K.: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 87 U.K.: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 88 U.K.: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 89 U.K.: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 90 U.K.: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 91 U.K.: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 92 Italy: Key Macro & Micro Indicators
Table 93 Italy.: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 94 Italy: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 95 Italy: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 96 Italy: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 97 Italy: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 98 Italy: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 99 Spain: Key Macro & Micro Indicators
Table 100 Spain: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 101 Spain: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 102 Spain: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 103 Spain: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 104 Spain: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 105 Spain: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 106 Estimated Number of New Cancer Cases - 2020 Vs 2030
Table 107 RoE: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 108 RoE: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 109 RoE: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 110 RoE: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 111 RoE: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 112 RoE: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 113 Asia-Pacific: NGS Services Market, by Country/Region, 2022–2031 (USD Million)
Table 114 Asia-Pacific: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 115 Asia-Pacific: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 116 Asia-Pacific: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 117 Asia-Pacific: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 118 Asia-Pacific: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 119 Asia-Pacific: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 120 China: Key Macro & Micro Indicators
Table 121 China: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 122 China: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 123 China: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 124 China: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 125 China: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 126 China: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 127 Japan: Key Macro & Micro Indicators
Table 128 Japan: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 129 Japan: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 130 Japan: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 131 Japan: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 132 Japan: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 133 Japan: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 134 India: Key Macro & Micro Indicators
Table 135 India: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 136 India: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 137 India: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 138 India: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 139 India: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 140 India: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 141 Estimated Number of New Cancer Cases - 2020 Vs 2030
Table 142 RoAPAC: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 143 RoAPAC: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 144 RoAPAC: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 145 RoAPAC: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 146 RoAPAC: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 147 RoAPAC: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 148 Latin America: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 149 Latin America: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 150 Latin America: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 151 Latin America: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 152 Latin America: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 153 Latin America: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 154 Middle East & Africa: NGS Services Market, by Type, 2022–2031 (USD Million)
Table 155 Middle East & Africa: NGS Services Market, by Technology, 2022–2031 (USD Million)
Table 156 Middle East & Africa: NGS Services Market, by Application, 2022–2031 (USD Million)
Table 157 Middle East & Africa: NGS Services Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 158 Middle East & Africa: NGS Services Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 159 Middle East & Africa: NGS Services Market, by End User, 2022–2031 (USD Million)
Table 160 Recent Developments, by Company, 2020–2023
Table 161 Key Services Offered by Companies Operating NGS Services Market: Competitive Benchmarking
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global NGS Services Market, by Type, 2024 Vs 2031 (USD Million)
Figure 8 Global NGS Services Market, by Technology, 2024 Vs 2031 (USD Million)
Figure 9 Global NGS Services Market, by Application, 2024 Vs 2031 (USD Million)
Figure 10 Global NGS Services Market, by End User, 2024 Vs 2031 (USD Million)
Figure 11 Global NGS Services Market, by Geography
Figure 12 Global NGS Services Market: Impact Analysis of Market Dynamics (2023–2030)
Figure 13 Pharmaceutical R&D Expenditures in the U.S., Europe, and China, 2010 Vs. 2019 Vs. 2020 (USD Million)
Figure 14 Global Pharmaceutical R&D Expenditure, 2016–2028 (USD Billion)
Figure 15 Estimated Number of New Cancer Cases, 2020–2040 (in Million)
Figure 16 Genome Sequencing Costs, 2010–2021 (USD)
Figure 17 Porter's Five Forces Analysis
Figure 18 EU Regulatory Pathway - IVDR 2017/746
Figure 19 China: Medical Device Classification and Premarket Requirements for NGS Instruments
Figure 20 Global NGS Services Market, by Type, 2024 Vs 2031 (USD Million)
Figure 21 Number of Manuscripts Featuring RNA Sequencing Per Year on PubMed
Figure 22 Applications of De Novo Sequencing
Figure 23 Global NGS Services Market, by Technology, 2024 Vs 2031 (USD Million)
Figure 24 Global NGS Services Market, by Application, 2024 Vs 2031 (USD Million)
Figure 25 U.S.: New Molecular Entity (NME) Approvals (2011–2022)
Figure 26 Estimated Number of New Cancer Cases Globally (2020–2040) (in Million)
Figure 27 Global NGS Services Market, by End User, 2024 Vs 2031 (USD Million)
Figure 28 Global Pharmaceutical R&D Spending, 2012–2026 (USD Billion)
Figure 29 Global NGS Services Market, by Geography, 2024 Vs 2031 (USD Million)
Figure 30 North America: NGS Services Market Snapshot
Figure 31 Pharmaceutical R&D Expenditure in the U.S. (2000-2020)
Figure 32 Pharmaceutical Industry R&D Expenditure in Europe (2020)
Figure 33 Europe: NGS Services Market Snapshot
Figure 34 Italy: Number of Biotechnology Companies, 2010-2021
Figure 35 RoE: Pharmaceutical R&D Expenditure, 2020
Figure 36 Asia-Pacific: NGS Services Market Snapshot
Figure 37 Key Growth Strategies Adopted by Leading Players, 2021–2024
Figure 38 NGS Services Market: Competitive Benchmarking, by Region
Figure 39 Global NGS Services Market Share Analysis, by Key Players, 2023 (%)
Figure 40 Competitive Dashboard: NGS Services Market
Figure 41 Illumina, Inc.: Financial Overview (2023)
Figure 42 Eurofins Scientific S.E.: Financial Overview (2023)
Figure 43 Invitae Corporation: Financial Overview (2023)
Figure 44 F. Hoffmann-La Roche AG: Financial Overview (2023)
Figure 45 Beijing Genomics Institute (BGI): Financial Overview (2023)
Figure 46 Novogene Co., Ltd.: Financial Overview (2023)
Figure 47 PerkinElmer, Inc.: Financial Overview (2023)
Figure 48 Macrogen, Inc.: Financial Overview (2023)
Figure 49 QIAGEN N.V.: Financial Overview (2023)
Figure 50 LGC Limited: Financial Overview (2023)
Figure 51 Azenta, Inc.: Financial Overview (2023)
Figure 52 DNA Link, Inc.: Financial Overview (2023)
Figure 53 Quest Diagnostics Incorporated: Financial Overview (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
DNA Sequencing Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Aug-2024
Sequencing Kits Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jan-2024
